Combination of biotransformation by P450 BM3 mutants with on-line post-column bioaffinity and mass spectrometric profiling as a novel strategy to diversify and characterize p38α kinase inhibitors

MedChemComm

Volumn 4, Issue 2, 2013, Pages 371-377

  Rea, Vanina ^a   Falck, David ^a   Kool, Jeroen ^a   De Kanter, Frans J J ^a   Commandeur, Jan N M ^a   Vermeulen, Nico P E ^a   Niessen, Wilfried M A ^a   Honing, Maarten ^a,b  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b DSM RESOLVE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 BM3; MITOGEN ACTIVATED PROTEIN KINASE 14 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MUTANT PROTEIN; TAK 715; TAK P 1; TAK P 10; TAK P 2; TAK P 3; TAK P 4; TAK P 5; TAK P 6; TAK P 7; TAK P 8; TAK P 9; UNCLASSIFIED DRUG;

ARTICLE; BACILLUS MEGATERIUM; BINDING AFFINITY; BINDING SITE; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG TRANSFORMATION; ENZYME ACTIVE SITE; ENZYME BINDING; HUMAN; LIVER MICROSOME; MASS SPECTROMETRY; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE;

BACILLUS MEGATERIUM; BACTERIA (MICROORGANISMS);

EID: 84876700577     PISSN: 20402503     EISSN: 20402511     Source Type: Journal    
DOI: 10.1039/c2md20283b     Document Type: Article

References (30)

1. M. Sawayama M. M. Chen P. Kulanthaivel M. S. Kuo H. Hemmerle F. H. Arnold A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds Chem.-Eur. J. 2009 15 11723 11729
2. A. Fura Y. Z. Shu M. Zhu R. L. Hanson V. Roongta W. G. Humphreys Discovering drugs through biological transformation: role of pharmacologically active metabolites in drug discovery J. Med. Chem. 2004 47 4339 4351
3. L. C. Wienkers T. G. Heath Predicting in vivo drug interactions from in vitro drug discovery data Nat. Rev. Drug Discovery 2005 4 825 833
4. D. A. Smith R. S. Obach Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment Chem. Res. Toxicol. 2009 22 267 279
5. C. M. Clouthier J. N. Pelletier Expanding the organic toolbox: a guide to integrating biocatalysis in synthesis Chem. Soc. Rev. 2012 41 1585 1605
6. F. Hollmann I. W. C. E. Arends K. Buehler A. Schallmey B. Buhler Enzyme-mediated oxidations for the chemist Green Chem. 2011 13 226 265
7. F. P. Guengerich Cytochrome P450 enzymes in the generation of commercial products Nat. Rev. Drug Discovery 2002 1 359 366
8. S. Kumar Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation Expert Opin. Drug Metab. Toxicol. 2010 6 115 131
9. A. W. Munro D. G. Leys K. J. McLean K. R. Marshall T. W. Ost S. Daff C. S. Miles S. K. Chapman D. A. Lysek C. C. Moser C. C. Page P. L. Dutton P450 BM3: the very model of a modern flavocytochrome Trends Biochem. Sci. 2002 27 250 257
10. C. J. Whitehouse S. G. Bell L. L. Wong P450(BM3) (CYP102A1): connecting the dots Chem. Soc. Rev. 2012 41 1218 1260
11. V. Rea A. J. Kolkman E. Vottero E. J. Stronks K. A. Ampt M. Honing N. P. E. Vermeulen S. S. Wijmenga J. N. M. Commandeur Active site substitution A82W improves the regioselectivity of steroid hydroxylation by cytochrome P450 BM3 mutants as rationalized by spin relaxation nuclear magnetic resonance studies Biochemistry 2012 51 750 760
12. H. Venkataraman S. B. A. de Beer D. P. Geerke N. P. E. Vermeulen J. N. M. Commandeur Regio- and stereoselective hydroxylation of optically active α-ionone enantiomers by engineered cytochrome P450 BM3 mutants Adv. Synth. Catal. 2012 354 2172 2184
13. B. M. A. van Vugt-Lussenburg E. Stjernschantz J. Lastdrager C. Oostenbrink N. P. E. Vermeulen J. N. M. Commandeur Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis J. Med. Chem. 2007 50 455 461
14. C. H. Yun K. H. Kim D. H. Kim H. C. Jung J. G. Pan The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities Trends Biotechnol. 2007 25 289 298
15. J. Reinen J. S. van Leeuwen Y. Li L. Sun P. D. Grootenhuis C. J. Decker J. Saunders N. P. E. Vermeulen J. N. M. Commandeur Efficient screening of cytochrome P450 BM3 mutants for their metabolic activity and diversity toward a wide set of drug-like molecules in chemical space. Drug Metab. Dispos. 2011 39 1568 1576
16. J. Kool M. Giera H. Irth W. M. A. Niessen Advances in mass spectrometry based post-column bioaffinity profiling of mixtures Anal. Bioanal. Chem. 2011 399 2655 2668
17. J. S. B. de Vlieger A. J. Kolkman K. A. Ampt J. N. M. Commandeur N. P. E. Vermeulen J. Kool S. S. Wijmenga W. M. A. Niessen H. Irth M. Honing Determination and identification of estrogenic compounds generated with biosynthetic enzymes using hyphenated screening assays, high resolution mass spectrometry and off-line NMR J. Chromatogr., B: Anal. Technol. Biomed. Life Sci. 2010 878 667 674
18. J. Reinen L. L. Kalma S. Begheijn F. A. H. Heus J. N. M. Commandeur N. P. E. Vermeulen Application of cytochrome P450BM3 mutants as biocatalysts for the profiling of estrogen receptor binding metabolites of the mycotoxin zearalenone Xenobiotica 2011 41 59 70
19. D. Falck J. S. B. de Vlieger W. M. A. Niessen J. Kool M. Honing M. Giera H. Irth Development of an online p38α mitogen-activated protein kinase binding assay and integration of LC-MS Anal. Bioanal. Chem. 2010 398 1771 1780
20. P. Cohen Protein kinases-the major drug targets of the twenty-first century? Nat. Rev. Drug Discovery 2002 1 309 315
21. A. Dorn V. Schattel S. Laufer Design, synthesis and SAR of phenylamino-substituted 5,11-dihydro-dibenzo[a,d]cyclohepten-10-ones and 11H-dibenzo[b,f]oxepin-10-ones as p38 MAP kinase inhibitors Bioorg. Med. Chem. Lett. 2011 20 3074 3077
22. S. Miwatashi Y. Arikawa K. Naruo K. Igaki Y. Watanabe H. Kimura T. Kawamoto S. Ohkawa Synthesis and biological activities of 4-phenyl-5-pyridyl-1, 3-thiazole derivatives as p38 MAP kinase inhibitors Chem. Pharm. Bull. 2005 53 410 418
23. S. Miwatashi Y. Arikawa E. Kotani M. Miyamoto K. Naruo H. Kimura T. Tanaka S. Asahi S. Ohkawa Novel inhibitor of p38 MAP kinase as an anti-TNF-alpha drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2- pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent J. Med. Chem. 2005 48 5966 5979
24. C. Ozdemir C. A. Akdis Discontinued drugs in 2006: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs Expert Opin. Invest. Drugs 2007 16 1327 1344
25. F. Verkaar A. A. van der Doelen J. F. Smits W. M. Blankesteijn G. J. Zaman Inhibition of Wnt/β-catenin signaling by p38 MAP kinase inhibitors is explained by cross-reactivity with casein kinase Iδ/ε. Chem. Biol. 2011 18 485 494
26. N. Barker H. Clevers Mining the Wnt pathway for cancer therapeutics Nat. Rev. Drug Discovery 2006 5 997 1014
27. D. Falck, J. Kool, M. Honing and W. M. A. Niessen, Comparison of (bio-)transformation techniques for the generation of metabolite-like new chemical entities. Part 2: Tandem mass spectrometry study of p38α kinase inhibitors and related substances, J. Mass Spectrom., in preparation
28. K. H. Ling G. A. Leeson S. D. Burmaster R. H. Hook M. K. Reith L. K. Cheng Metabolism of terfenadine associated with CYP3A(4) activity in human hepatic microsomes Drug Metab. Dispos. 1995 23 631 636
29. K. H. Liu M. G. Kim D. J. Lee Y. J. Yoon M. J. Kim J. H. Shon C. S. Choi Y. K. Choi Z. Desta J. G. Shin Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A Drug Metab. Dispos. 2006 34 1793 1797
30. B. Y. Zhu Z. J. Jia P. Zhang T. Su W. Huang E. Goldman D. Tumas V. Kadambi P. Eddy U. Sinha R. M. Scarborough Y. Song Inhibitory effect of carboxylic acid group on hERG binding Bioorg. Med. Chem. Lett. 2006 16 5507 5512